Sanquin Blood Bank South West Region
Rotterdam, 3001 KJ, Netherlands
NCT Number: NCT00335023
Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 4
Rotterdam, 3001 KJ, Netherlands
The WOMB study is a multicenter trial in patients with PPH, where a restrictive RBC transfusion policy will be compared with a more liberal RBC transfusion policy. Primary outcome in this study is fatigue measured with the MFI questionnaire. Inclusion criteria are: 1) 12-24 h after VD or CS; 2) 4.8 ≤Hb≤ 7.9 g/dL; 3) blood loss ≥ 1000mL or Hb decrease ≥ 1,9 g/dL; 4) age≥ 18 years; 5) no anaemic symptoms. Patients will be randomised for a RBC transfusion or not. The total follow-up period is 6 weeks. HRQoL will be measured at T=0 (12-24 hours postpartum) 3 days, 1, 3 and 6 weeks postpartum. At T=0 and 6 weeks postpartum Hb value will be measured. For the patients who receive a RBC transfusion, the effect of the RBC transfusion will be measured with the Hb value, Hct, platelet and leukocyte count, and the temperature of the patient before and after the RBC transfusion. The sample size is 500 patients: 250 allocated to a RBC transfusion and 250 patients allocated to a restrictive policy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
Time frame: on day 3 postpartum
measured with the MFI questionnaire
Time frame: delivery - six weeks postpartum
Health related quality of life measured with the following questionnaires: Euro-Qol, SF-36 and the MFI
Time frame: delivery - six weeks postpartum
Time frame: before- after transfusion
Hb value and platelet count will be measured before and after red blood cell transfusion
Time frame: before- after transfusion
heart beat per minute, blood pressure, temperature will be measured before and after red blood cell transfusion
Time frame: delivery - six weeks postpartum
the hospital stay after delivery will be compared between both arms. All admissions in the first 6 weeks postpartum will be registered
Time frame: delivery - six weeks postpartum
all complications and admissions in the first 6 weeks postpartum will be registered
Sanquin Research & Blood Bank Divisions
Other
Acronym: WOMB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05448456
Anemia, Early Postpartum Hemorrhage
Ashdod, Shfela, Israel
View Trial DetailsNCT02797353
Anemia, Antepartum Hemorrhage
View Trial DetailsNCT02101567
Anemia, Bleeding
Cairo, Egypt
View Trial DetailsNCT00120237
Anemia, Female Urogenital Diseases and Pregnancy Complications
Chitral, Chitral District, Pakistan
View Trial Details